Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The EphA2 receptor tyrosine kinase is frequently overexpressed and functionally altered in malignant cells and thus provides opportunities for selective targeting of tumor cells. We describe here the development of a novel, bispecific single-chain antibody (bscAb) referred to as bscEphA2xCD3. This molecule simultaneously targets EphA2 on tumor cells and the T-cell receptor/CD3 complex on T cells and possesses structural and functional characteristics of the recently developed BiTE technology. An EphA2-specific single-chain antibody was selected for recognition of an epitope that is preferentially exposed on malignant cells based on the concept of epitope exclusion; this was fused to a CD3-specific single-chain antibody to generate bscEphA2xCD3. The resultant bscAb redirected unstimulated human T cells to lyse EphA2-expressing tumor cells both in vitro and in vivo. In separate experiments, efficient tumor cell lysis was achieved in vitro at drug concentrations ≤1 μg/mL, at a low T-cell effector-to-tumor target cell ratio (1:1), and with tumor cells that possess few available binding sites (2,400 per cell) for bscEphA2xCD3. Time-lapsed microscopy revealed potent cytotoxic activity of bscEphA2xCD3-activated T cells against monolayers of malignant cells but not against monolayers of nontransformed EphA2-positive cells except at the edges of the monolayer where the target epitope was exposed. BscEphA2xCD3 was also efficacious in human xenograft mouse models modified to show human T-cell killing of tumors. Together, our results reveal opportunities for redirecting the potent activity of cytotoxic T cells towards tumor cells that express selectively accessible epitopes and establish EphA2-specific bscAb molecules as novel and potent therapeutics with selectivity for tumor cells. [Cancer Res 2007;67(8):3927–35]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The discovery of receptor tyrosine kinases: targets for cancer therapy
Gschwind, A., Fischer, O. M., & Ullrich, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1360 · Cited by 1,227 · cited 1×
“Receptor tyrosine kinases, including epidermal growth factor receptor and HER2, have been validated as particularly good targets for antibody-based therapy (19).”
BackgroundLöffler, A., Kufer, P., Lutterbüse, R., Zettl, F., Daniel, P. T., Schwenkenbecher, J. M., Riethmüller, G., Dörken, B., & Bargou, R. C. (2000) · Blood · doi:10.1182/blood.v95.6.2098 · Cited by 445 · cited 3×
“EphA2specific bscAb molecules were constructed from the VH and VL domains that were cloned from the mouse hybridoma EA2 (18) into the expression vector pEF-DHFR using the methods described previously ( 29 ).”
MethodInfluentialSelf-citationOffner, S., Hofmeister, R., Romaniuk, A., Kufer, P., & Baeuerle, P. A. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.03.007 · Cited by 365
Self-citationHoffmann, P., Hofmeister, R., Brischwein, K., Brandl, C., Crommer, S., Bargou, R., Itin, C., Prang, N., & Baeuerle, P. A. (2005) · International Journal of Cancer · doi:10.1002/ijc.20908 · Cited by 344
Self-citationBiTEs: bispecific antibody constructs with unique anti-tumor activity
Wolf, E., Hofmeister, R., Kufer, P., Schlereth, B., & Baeuerle, P. A. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03554-3 · Cited by 260 · cited 5×
“highly potent tumoricidal effects of diverse bscAbs of the BiTE class (27), we designed a new EphA2/CD3–specific bscAb from an EphA2-specific antibody, which recognizes an epitope that is preferentially exposed on transformed cells (18).”
BackgroundInfluentialSelf-citationBrischwein, K., Schlereth, B., Guller, B., Steiger, C., Wolf, A., Lutterbuese, R., Offner, S., Locher, M., Urbig, T., Raum, T., et al. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.07.034 · Cited by 256
Self-citationDreier, T., Baeuerle, P. A., Fichtner, I., Grün, M., Schlereth, B., Lorenczewski, G., Kufer, P., Lutterbüse, R., Riethmüller, G., Gjorstrup, P., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.8.4397 · Cited by 191
Self-citationSchlereth, B., Fichtner, I., Lorenczewski, G., Kleindienst, P., Brischwein, K., da Silva, A., Kufer, P., Lutterbuese, R., Junghahn, I., Kasimir-Bauer, S., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2637 · Cited by 132
Self-citationThe clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas
Han, L., Dong, Z., Qiao, Y., Kristensen, G. B., Holm, R., Nesland, J. M., & Suo, Z. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.06.036 · Cited by 68
Cited by
Bispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303
Eph receptors and ephrins in cancer: bidirectional signalling and beyond
Pasquale, E. B. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2806 · Cited by 1,226
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., et al. (2008) · Science · doi:10.1126/science.1158545 · Cited by 1,078
Self-citationBispecific T‐cell engagers for cancer immunotherapy
Huehls, A. M., Coupet, T. A., & Sentman, C. L. (2015) · Immunology & Cell Biology · doi:10.1038/icb.2014.93 · Cited by 466
The EphA2 Receptor and EphrinA1 Ligand in Solid Tumors: Function and Therapeutic Targeting
Wykosky, J., & Debinski, W. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0244 · Cited by 300
Metadata
- Authors
- Hammond, S. A., Lutterbuese, R., Roff, S., Lutterbuese, P., Schlereth, B., Bruckheimer, E., Kinch, M. S., Coats, S., Baeuerle, P. A., Kufer, P., & Kiener, P. A.
- Venue
- Cancer Research
- Published
- 2007-04-15
- Volume
- 67
- Issue
- 8
- Pages
- 3927-3935
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2160692925
- Cited by
- 81
- References
- 9
- FWCI
- 5.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct. https://app.cochat.ai/papers/10.1158/0008-5472.can-06-2760
- The paper
- Hammond, S. A., Lutterbuese, R., Roff, S., Lutterbuese, P., Schlereth, B., Bruckheimer, E., Kinch, M. S., Coats, S., Baeuerle, P. A., Kufer, P., & Kiener, P. A. (2007). Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct. Cancer Research. https://doi.org/10.1158/0008-5472.can-06-2760
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.